We are an international biopharmaceutical company engaged in the discovery and development of therapies designed to extend and enhance the quality of human life. Through the application of our proprietary technologies, we have established a pipeline of product development programs in multiple disease areas, primarily focused in the field of regenerative medicine. We are committed to developing therapeutic products that we believe have best-in-class potential, meaning therapies that have the potential to be safer and more effective than the current standard of care or other products in development, and that may have other advantages, such as superior scalability or ease of administration. Our lead product development programs utilize MultiStem®, a proprietary “off the shelf” stem cell product that has shown promise for treating indications in the inflammatory and immune, neurological, and cardiovascular disease areas, as well as certain other conditions. MultiStem is currently being evaluated in several clinical stage programs, as well as in a range of preclinical programs. In addition, we are developing novel pharmaceuticals to treat indications such as obesity and related metabolic conditions, and certain neurological disorders.
We are committed to scientific excellence, patient safety, and developing safer and more effective therapies that can address significant unmet medical needs and enhance the lives of patients. We believe that this commitment will enable us to create substantial value for our shareholders. Athersys was established in October 1995, and since 2007, has been a publicly-traded company with its common stock traded on the NASDAQ Capital Market under the symbol “ATHX”. Athersys has operations in Cleveland, Ohio and Leuven, Belgium.